Clinical trial
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
NCT03093428
Study timeline
Study start (actual)2017-06-09Date precision: day
Registry last updated2025-03-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
Radium-223DRUG
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Dana-Farber Cancer Institutelead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03093428 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.